The identification of CD8+ TIGR cells yields new insights into organ-specific immune regulation and potential therapeutics for inflammatory bowel disease.

Cellares will adapt and automate the SBT-77-7101 manufacturing process from Sonoma for use with Cell Shuttle.

Cellares, the first Integrated Development and Manufacturing Organization (IDMO), and Sonoma Biotherapeutics, Inc., a ...

Forte Biosciences' FBRX shares surged 78.3% after the company reported positive top-line results from a phase Ib study ...

The study of regulatory T (Treg) cells in immunology has revealed their fundamental importance in shaping immune responses during viral infections. Treg ...

CoRegen, Inc., a biopharmaceutical company pursuing novel treatments for patients living with some of the most aggressive forms of cancer, today announced the U.S. Food and Drug Administration (FDA) ...

Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with ...

Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with ...

As CEO of Coya Therapeutics, Dr Arun Swaminathan is steering the company’s lead programme, COYA 302, an immune-modulating combination designed to restore regulatory T-cell function and dampen ...

Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, announces the initiation of the blinded ...

A special group of immune cells known as regulatory T cells, or Tregs for short, became an overnight sensation when a trio of U.S. and Japanese scientists won the Nobel Prize in physiology or medicine ...